European Commission approves Alecensa as the adjuvant treatment for people with ALK-positive early-stage lung cancer June 18, 2024
Tagrisso with the addition of chemo recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer June 11, 2024
European Commission Approves Opdivo, Cisplatin and Gemcitabine combo for the 1L Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma June 4, 2024
WITHDRAWN: FDA withdraws accelerated approval to infigratinib for metastatic cholangiocarcinoma May 21, 2024
FDA approves Imdelltra™ (tarlatamab-dlle) for The Treatment Of Extensive-Stage Small Cell Lung Cancer May 21, 2024
Approvals received for BRAFTOVI and MEKTOVI for Expanded Use for Two New Indications in Japan May 21, 2024
FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer May 15, 2024
CARVYKTI (ciltacabtagene autoleucel) Approved by the European Commission for 2L Treatment of Patients with R/R Multiple Myeloma May 1, 2024
Vebreltinib approved in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene May 1, 2024
FDA approves Lutathera® for pediatric patients with gastroenteropancreatic neuroendocrine tumors May 1, 2024
OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for R/R BRAF-altered Pediatric Low-Grade Glioma (pLGG) May 1, 2024
XTANDI (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting May 1, 2024
FDA Approves Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer April 23, 2024
U.S. FDA Approves Abecma for Triple-Class Exposed R/R Multiple Myeloma After Two Prior Lines of Therapy April 8, 2024
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours April 8, 2024
CARVYKTI® Approved by the U.S. FDA for Patients with R/R Multiple Myeloma Who Have Received at Least One Prior Line of Therapy April 8, 2024
European Commission Approves KEYTRUDA + Chemo as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable NSCLC at High Risk of Recurrence in Adults April 2, 2024
Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer April 2, 2024
